TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04259944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAPOX
Description: DAY 1~* OXA 130 mg/m2 administered as intravenous infusion over 2 hours in 250 mL dextrose 5%~* CAPE 1000 mg/m2 administrated per os twice daily~DAY 2-14~• CAPE 1000 mg/m2 os twice daily~Cycle length is 3 weeks comprising 2 hours of oxaliplatin infusion every 21 days, 14 days of oral capecitabine and 7 days of resting.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: DAY 1-14~• CAPE 1250 mg/m2 os twice daily~Cycle length is 3 weeks comprising 14 days of oral capecitabine and 7 days of resting.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: Day 1:~* IRI, 180 mg/m2 administered as iv infusion over 30-90 minutes in 250 mL dextrose 5%, concurrently (via a Y-connector) with~* LV, 400 mg/m2 administered as an iv infusion over 2 hours, in 250 mL dextrose 5%, followed by~* 5-FU, 400 mg/m2 administered as a bolus injection (iv push administered by hand) and then at 2400 mg/m2 administered as a iv infusion over 46 hours.~Cycle length is 2 weeks comprising approximately 48 hours of infusion and 12 days of rest.
Study: NCT00297336

Intervention type: DRUG
Intervention: Topiramate
Description: 80 patients with diagnosed with migraine
Study: NCT02538159

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CVC
Description: The inclusion of any CVC is an aseptic technique, so hand washing, mask, cap is required, sterile gloves and scoping insertion using sterile drapes. The skin disinfection is carried out with 2% chlorhexidine alcohol 17, to be dried completely before insertion of the catheter (30 seconds). No prophylactic antibiotic was administered before insertion. In the case of CVC, the subclavian vein of choice will be followed by the femoral and jugular. Seldinger technique with direct radiation control in the operating room is used.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PICC
Description: The inclusion of any PICC is an aseptic technique, so hand washing, mask, cap is required, sterile gloves and scoping insertion using sterile drapes. The skin disinfection is carried out with 2% chlorhexidine alcohol 17, to be dried completely before insertion of the catheter (30 seconds). No prophylactic antibiotic was administered before insertion. PICC vein of choice is the basilica vein with help of Ecography in the interventional radiology room.
Study: NCT05660343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozonized Olive Oil Solutions
Description: (0.03PPM ozone + 6-6.5 PH olive oil, viscosity at 25°C 55mPas, relative density gr/ml (20°C) 0.98 pycnometer, 100 ml bottle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozonized Olive Oil Solutions
Description: (0.03PPM ozone + 6-6.5 PH olive oil, viscosity at 25°C 55mPas, relative density gr/ml (20°C) 0.98 pycnometer, 100 ml bottle.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Level Laser LLL Therapy
Description: (0.03PPM ozone + 6-6.5 PH olive oil, viscosity at 25°C 55mPas, relative density gr/ml (20°C) 0.98 pycnometer, Ozonated olive oil, 100 ml bottle, and 810 nm diode laser, 3.4 j/cm2 energy density, 0.5w power, CHEESE DEN7A/DEN4A 810, 2 min for each side
Study: NCT04247763

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saturated Fat Meal

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saturated Fat Meal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oleic Sunflower Oil Meal

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oleic Sunflower Oil Meal
Study: NCT00537654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment sequence A
Description: Commercially available tamsulosin hydrochloride 0.4 mg and dutasteride 0.5 mg in a fed state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment sequence B
Description: Fixed dose combination formulation of dutasteride and tamsulosin hydrochloride (0.5 mg dutasteride, 0.4 mg tamsulosin hydrochloride) in a fed state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment sequence C
Description: Commercially available tamsulosin hydrochloride 0.4 mg and dutasteride 0.5 mg in a fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment sequence D
Description: Fixed dose combination formulation of dutasteride and tamsulosin hydrochloride (0.5 mg dutasteride, 0.4 mg tamsulosin hydrochloride) in a fasted state
Study: NCT05333692

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fresubin® Protein Energy DRINK
Description: 1-2 bottles of Fresubin® Protein Energy DRINK per day

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: NEPRO® , Abbott
Description: 2-4 cans NEPRO® per day
Study: NCT02293564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gevokizumab
Description: Solution for subcutaneous injection
Study: NCT04976504

Intervention type: DEVICE
Intervention: Oxygen reserve index
Description: This is an observational study of the routine clinical practice with no specific additional interventions required. The investigators enrolled the ASA physical status I to III patients scheduled for elective surgery with planned arterial catheter placement before induction. ORi and standard monitors were placed. The patients were preoxygenated and received anesthesia induction as routine clinical practice. Intubation was done by video-laryngoscope. The endotracheal tube was not connected to the breathing circuit to avoid apneic oxygenation. Ventilation was resumed when SpO2 fell to 90%. ORi and SpO2 were recorded every ten seconds.
Study: NCT04192903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide combined with Cisplatin
Description: Chidamide: 30mg,PO,biw one week before cycle 1 treatment Cisplatin 75mg/m2 ivgtt D1 Chidamide :20mg PO Biw, 2 week on , 1 week off
Study: NCT02984293

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin 80 mg once daily for 28 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily for 28 days.
Study: NCT03446820

Intervention type: OTHER
Group type: OTHER
Intervention: hygro cotton sheets
Description: hygro cotton sheets will be utilized to impact microclimate
Study: NCT02037464

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Capsaicin Supplement (Cayenne by Nature's Way)
Description: One capsule of the supplement to be taken twice daily.
Study: NCT00710359

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxycobalamin (Vitamin B12 Depot, Nycomed Pharma)
Description: 400 µg hydroxycobalamin (Vitamin B12 Depot, Nycomed Pharma), as a single intramuscular injection

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Hydroxycobalamin (Vitamin B12 Depot, Nycomed Pharma)
Description: 400 µg hydroxycobalamin (Vitamin B12 Depot, Nycomed Pharma), as a single intramuscular injection
Study: NCT03506685

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry needling and STM
Description: dry needling and soft tissue mobilization
Study: NCT06193304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eliglustat
Description: Pharmaceutical form:solution -Route of administration: Oral wihtout ingestion
Study: NCT01250366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Capsules, Oral, 1000 or 1200 mg daily (delivered in weight-adjusted am/pm divided dose), 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Capsules, Oral, 1000 or 1200 mg daily (delivered in weight-adjusted am/pm divided dose), 7 days
Study: NCT00540046

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Copper T 380A IUD
Description: Copper T 380A IUD will be placed at the 2-4 week post-operative visit.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Copper T 380A IUD
Description: Copper T 380A IUD will be placed at the 2-4 week post-operative visit.
Study: NCT04265820

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: unilateral implantation of IOL
Description: unilateral phacoemulsification and implantation of IOL.IOL may be monofocal,bifocal ,or trifocal，according to the patients preference and the eyes condition.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: bilateral implantation of IOL
Description: bilateral phacoemulsification and implantation of IOL.IOL may be monofocal,bifocal ,or trifocal，according to the patients preference and the eyes condition.
Study: NCT02792751

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bispectral Index Monitorisation (BIS)
Description: Standard monitoring was performed with electrocardiography, pulse oximetry and non invasive blood pressure. Additionally, Bispectral index (Aspect Medical Systems, Natica, MA) electrodes were connected to Group B patients

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ramsey Sedation Scale
Description: Propofol administration was done to keep the Ramsey Sedation scale of 3 or 4
Study: NCT03871023

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Smith & Nephew PICO Negative wound pressure versus standard dresing
Description: To investigate if negative wound pressure improves wound outcome

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Smith & Nephew PICO Negative wound pressure versus standard dresing
Description: To investigate if negative wound pressure improves wound outcome

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PREVENA Negative pressure wound versus standard dressing
Description: To investigate if negative wound pressure improves wound outcome

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PREVENA Negative pressure wound versus standard dressing
Description: To investigate if negative wound pressure improves wound outcome
Study: NCT04114864

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Psycho-educational sessions
Description: Participants of clusters allocated to the ME-WE intervention group will complete a programme based on seven weekly sessions of approximately 2 hours each, plus a follow-up meeting after 3 months from the end of the programme. All sessions maintain a similar structure (objectives, ice-breaker, central activity/ies, and final activity). At the end of some sessions, participants will be asked to do some exercises at home, between one meeting and the next one, in order to keep what has been done during the previous session fresh in their minds.~Contents of sessions will be as follows: (1) Getting to know each other; (2) The Advisor: dealing with annoying thoughts; (3) The Noticer: being in connection with our feelings; (4) The Discoverer: growing and thriving; (5) Values: connecting to meaning and vitality; (6) Developing a flexible self-view and self-compassion; (7) Building strong social networks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psycho-educational sessions
Description: Participants of clusters allocated to the ME-WE intervention group will complete a programme based on seven weekly sessions of approximately 2 hours each, plus a follow-up meeting after 3 months from the end of the programme. All sessions maintain a similar structure (objectives, ice-breaker, central activity/ies, and final activity). At the end of some sessions, participants will be asked to do some exercises at home, between one meeting and the next one, in order to keep what has been done during the previous session fresh in their minds.~Contents of sessions will be as follows: (1) Getting to know each other; (2) The Advisor: dealing with annoying thoughts; (3) The Noticer: being in connection with our feelings; (4) The Discoverer: growing and thriving; (5) Values: connecting to meaning and vitality; (6) Developing a flexible self-view and self-compassion; (7) Building strong social networks.
Study: NCT01244854

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Life Goals Collaborative Care
Description: LGCC consists of 1) 10 sessions focused on CVD risk reduction through behavioral change within the context of patients' psychiatric symptoms; 2) participant goal setting in diet and exercise; 3) customized ongoing motivational interviewing (MI)-based patient contacts with a health specialist for 6 months, in addition to 4) strategies to increase provider access and support for behavioral change and medical management.
Study: NCT03954392

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy with social cognitive training (CBT+SCT)
Description: The cognitive behavioral therapy is based on Beck's cognitive therapy model for the treatment of depression. We will conduct individual therapy based on the Coping with Stress manual used in other depression treatment studies with adolescents. In addition, the investigators will teach the teen explicitly about theory of mind and social perspective taking during each session and we will use examples from their own life to help them learn the skills.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT-only
Description: The cognitive behavioral therapy is based on Beck's cognitive therapy model for the treatment of depression. The investigators will conduct individual therapy based on the Coping with Stress manual used in other depression treatment studies with adolescents.
Study: NCT03436251

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Local Hyperthermia at 37℃
Description: As a control, for patients with HPV+/CIN-1 or HPV+ with normal cytology, hyperthermia at 37℃ is applied

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LEEP or cold knife
Description: For patients with HPV+ / CIN-2

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Local Hyperthermia at 44℃
Description: As an experimental arm, for patients with HPV+/CIN-1/CIN2 or HPV+ with normal cytology

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Local Hyperthermia at 44℃
Description: As an experimental arm, for patients with HPV+/CIN-1/CIN2 or HPV+ with normal cytology
Study: NCT02047903

Intervention type: DRUG
Intervention: Afatinib
Description: 50, 40, 30 or 20 mg
Study: NCT02588300

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Drug induced sleep endoscopy
Description: Titration of propofol using a target controlled Infusion pump and description of the upper airway according to the VOTE classification
Study: NCT04212273

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Diagnostic Sonazoid-CEUS and EOB-MRI
Description: Undergo Sonazoid-CEUS and EOB-MRI
Study: NCT01285817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib, Vinblastine, Cyclophosphamide , methotrexate ,
Study: NCT03725631

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Imaging and serologic evaluation of fibrosis and steatosis
Description: Imaging evaluation: Fibroscan, MRI scan for evaluation of fibrosis and steatosis in biopsy proven NAFLD patients Serologic evaluation: serologic test for evaluation of fibrosis and steatosis in biopsy proven NAFLD patients
Study: NCT04860167

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Injection propofol was given to keep the BIS value 60-80 during the ERCP procedure
Study: NCT04934501

Intervention type: DIAGNOSTIC_TEST
Intervention: High-frame-rate contrast-enhanced ultrasound measurements (echoPIV)
Description: Patients will undergo high-frame-rate contrast-enhanced ultrasound measurements, within 6 to 8 weeks after the endovascular procedure, at the vascular center of Rijnstate hospital. Prior to these measurements a venous cannula will be placed to ensure venous access for the contrast administration.

Intervention type: DIAGNOSTIC_TEST
Intervention: Computed tomography angiography (CTA) scan
Description: Patients will undergo a CTA scan of the lower extremities at the Radiology dept. of Rijnstate hospital the same day as the echoPIV measurements. This CTA scan serves as a reference for the vessel geometry and stent location.
Study: NCT01908686

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pivotal Response Training
Description: Behavioral intervention for autism
Study: NCT03654794

Intervention type: BIOLOGICAL
Intervention: Cell pharmacokinetics of tacrolimus
Description: Three levels of tacrolimus will be tested. Each aliquot will be supplemented with an amount of tacrolimus to achieve one of these three levels of concentration.~At 0, 5, 15, 30, 60, 120, 240mn, the samples will be separated into 2 aliquots : one dedicated to the determination of tacrolimus in mononuclear cells, the other dedicated to the determination of calcineurin activity. in mononuclear cells.
Study: NCT03515525

Intervention type: DIAGNOSTIC_TEST
Intervention: Closed-suction drain fluid volume
Description: To evaluate the clinical value of postoperative drain fluid volume for detection of hematoma, an intra-individual comparison of drain secretion volumes between sides affected by hematoma and the uneventful contralateral breasts was performed.
Study: NCT04860167

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac Sodium and Lignocaine 10 % spray
Description: Injection Diclofenac sodium was given in the preoperative area 30 minutes before the procedure and four squirts of 10% lignocaine were given 5 minutes prior to the start of the procedure
Study: NCT01747993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin (0.4 mg/j)
Description: (1 tablet / day for 6 days)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: (1 tablet / day for 6 days)
Study: NCT01942590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clenbuterol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02880384

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FilmArray LRTI v.2.0 IUO Panel
Description: Patients will provide sputum or sputum equivalent to be probed with FilmArray LRTI v.2.0 IUO Panelpanel.
Study: NCT02592408

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ASP
Description: 3 days of artesunate sulfadoxine/pyrimethamine on days 0-2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ASP
Description: 3 days of artesunate sulfadoxine/pyrimethamine on days 0-2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ASP
Description: 3 days of artesunate sulfadoxine/pyrimethamine on days 0-2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ASP
Description: 3 days of artesunate sulfadoxine/pyrimethamine on days 0-2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SDPQ
Description: single dose primaquine on day 2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 14DPQ
Description: 14 day primaquine starting on day 2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 14DPQ on Day 42
Description: 14 day primaquine starting on day 42
Study: NCT01182467

Intervention type: RADIATION
Intervention: PET-CT scan
Description: PET-CT scan performed at baseline to determine SUV-max
Study: NCT00644046

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: multidisciplinary predialysis education
Description: teaching of renal knowledges, dietary support and recall of period medical visits
Study: NCT01858792

Intervention type: DRUG
Intervention: Belimumab 1 mg/kg
Description: Belimumab 1 mg/kg IV plus standard therapy; belimumab 1 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 72 weeks.

Intervention type: DRUG
Intervention: Belimumab 1 mg/kg
Description: Belimumab 1 mg/kg IV plus standard therapy; belimumab 1 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 72 weeks.

Intervention type: DRUG
Intervention: Belimumab 10 mg/kg
Description: Belimumab 10 mg/kg IV plus standard therapy; belimumab 10 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 72 weeks.

Intervention type: DRUG
Intervention: Belimumab 10 mg/kg
Description: Belimumab 10 mg/kg IV plus standard therapy; belimumab 10 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 72 weeks.

Intervention type: OTHER
Intervention: Placebo
Description: Placebo IV plus standard therapy; placebo administered on Days 0, 14, 28, and every 28 days thereafter through 72 weeks.

Intervention type: OTHER
Intervention: Placebo
Description: Placebo IV plus standard therapy; placebo administered on Days 0, 14, 28, and every 28 days thereafter through 72 weeks.
Study: NCT00276263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarcosine (N-methylglycine)
Description: Randomization to two treatment groups. One group treated with sarcosine 2 g/day for 16 weeks, the other group treated with placebo 2 g/day for 16 weeks.
Study: NCT03148613

Intervention type: DEVICE
Group type: OTHER
Intervention: Carbon Monoxide Breath Sensor System (COBSS)
Description: Carbon Monoxide Breath Sensor System (COBSS): Device to measure carbon monoxide levels in one's breath and inform the user.
Study: NCT00527592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)
Description: Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop, single dose. Referred to as travoprost.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost ophthalmic solution 0.005% (XALATAN®)
Description: Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop, single dose. Referred to as latanoprost.
Study: NCT00456677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: minocycline
Description: addition of antibiotic minocycline as antiinflammatory agent in addition to standard of care regimen.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Addition of oral placebo capsule in addition to standard of care regimen
Study: NCT03914612

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Administration
Description: Given IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies